<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611433644</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611433644</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alteration in Mean Platelet Volume and Platicrit Values in Patients With Cancer That Developed Thrombosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mutlu</surname>
<given-names>Hasan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611433644">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611433644"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Artış</surname>
<given-names>Tarık A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1076029611433644">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Erden</surname>
<given-names>Abdülsamet</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1076029611433644">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akca</surname>
<given-names>Zeki</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-1076029611433644">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029611433644">
<label>1</label>Department of Medical Oncology, Kayseri Training and Research Hospital, Kayseri, Turkey</aff>
<aff id="aff2-1076029611433644">
<label>2</label>Department of General Surgery, Erciyes University Faculty of Medicine, Kayseri, Turkey</aff>
<aff id="aff3-1076029611433644">
<label>3</label>Department of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey</aff>
<aff id="aff4-1076029611433644">
<label>4</label>Department of Radiation Oncology, Mersin Government Hospital, Mersin, Turkey</aff>
<author-notes>
<corresp id="corresp1-1076029611433644">Hasan Mutlu, Department of Medical Oncology, Kayseri Education and Research Hospital, Kayseri 38010, Turkey. Email: <email>doktorhasanmutlu@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>331</fpage>
<lpage>333</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>

</permissions>
<abstract>
<p>Mean platelet volume (MPV) is an indicator of thrombocyte volume and tendency to thrombosis can be mentioned in case of MPV elevation. Cancers are one of the important groups of thrombotic diseases. In the present study, MPV value was scrutinized in patients with cancer that developed thrombosis. Totally 43 patients followed in Kayseri Training and Research Hospital, in who thromboembolus has been developed, were prospectively recruited in the study. Thrombocyte, MPV, and platicrit (PCT) values were recorded at the time of cancer diagnosis and thrombosis development. Frequency analysis, crosstabs, and paired samples <italic>t</italic> test were used. Analyses showed that MPV values at the time of thrombosis development were significantly low as compared to those at the time of cancer diagnosis (<italic>P</italic> = .041). Thrombocyte count and PCT values were also low but not significant. The result of the present study is likely to show that thrombocytes have ignorable effect on thrombosis development in patients with cancer.</p>
</abstract>
<kwd-group>
<kwd>deep venous thrombosis</kwd>
<kwd>thrombosis</kwd>
<kwd>thrombosis prophylaxis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1076029611433644">
<title>Introduction</title>
<p>Thrombocytes play an important role in arterial and venous thromboses and in atherosclerotic complications.<sup><xref ref-type="bibr" rid="bibr1-1076029611433644">1</xref></sup> Mean platelet volume (MPV) is an indicator of thrombocyte volume and a marker of thrombocyte function. In case of MPV elevation, larger platelets with more dense granules and that produce more thromboxane A2 are present in blood circulation.<sup><xref ref-type="bibr" rid="bibr2-1076029611433644">2</xref></sup> In vitro response to adenosine diphosphate and collagen is high and tendency toward aggregation is high as well.<sup><xref ref-type="bibr" rid="bibr3-1076029611433644">3</xref></sup></p>
<p>In the literature, MPV elevation has been reported in myocardial infarction,<sup><xref ref-type="bibr" rid="bibr4-1076029611433644">4</xref></sup> cerebrovascular thromboembolus,<sup><xref ref-type="bibr" rid="bibr5-1076029611433644">5</xref></sup> pulmonary hypertension,<sup><xref ref-type="bibr" rid="bibr6-1076029611433644">6</xref></sup> diabetes mellitus,<sup><xref ref-type="bibr" rid="bibr7-1076029611433644">7</xref></sup> inactive chronic hepatitis B patients,<sup><xref ref-type="bibr" rid="bibr8-1076029611433644">8</xref></sup> and in smokers.<sup><xref ref-type="bibr" rid="bibr9-1076029611433644">9</xref></sup></p>
<p>Association between cancer and thrombosis was first defined in 1985 by Armand Trousseau. Thromboembolus is seen in approximately 11% of patients with cancer<sup><xref ref-type="bibr" rid="bibr10-1076029611433644">10</xref></sup> and has been defined as the second leading cause of deaths from cancer following infection.<sup><xref ref-type="bibr" rid="bibr11-1076029611433644">11</xref></sup> When the patients that have been hospitalized because of venous thrombosis or pulmonary embolus were investigated, it was seen that the number of patients with malignancy was higher than that without malignancy.<sup><xref ref-type="bibr" rid="bibr12-1076029611433644">12</xref></sup></p>
<p>The risk of venous thromboembolism (VTE) is 4- to 6-fold higher in patients with cancer.<sup><xref ref-type="bibr" rid="bibr13-1076029611433644">13</xref>,<xref ref-type="bibr" rid="bibr14-1076029611433644">14</xref></sup> Previous deep vein thrombosis, type of cancer, stage of cancer (localized vs distant metastasis), time from the diagnosis of cancer (greatest within the first 3 months), surgery, radiation therapy (pelvic radiation relative risk 2.0), and chemotherapy/biologic therapy/anti-angiogenesis/other agents are the factors that affect the risk of VTE development.<sup><xref ref-type="bibr" rid="bibr15-1076029611433644">15</xref></sup> A pre-chemotherapy thrombocyte count higher than 350 000/mm<sup><xref ref-type="bibr" rid="bibr3-1076029611433644">3</xref></sup>, elevated C-reactive protein, and acquired prothrombotic mutations increase the incidence of thrombosis.<sup><xref ref-type="bibr" rid="bibr16-1076029611433644">16</xref></sup> Venous thromboembolism, which is an important predictive factor in terms of survival, shortens the survival of patients with cancer.<sup><xref ref-type="bibr" rid="bibr17-1076029611433644">17</xref></sup> VTE in solid tumors are the most frequently seen in the tumors of lung, gastrointestinal system, and cerebral and renal system.<sup><xref ref-type="bibr" rid="bibr18-1076029611433644">18</xref></sup></p>
<p>Arterial thromboembolism is less common than VTE, with a rate changing between 3.0% and 5.2%; its incidence in hospitalized patients with neutropenic cancer has been identified<sup><xref ref-type="bibr" rid="bibr19-1076029611433644">19</xref></sup> as 1.9%. The risk of arterial thromboembolus has been significantly increased in chemotherapy combinations including Bevacizumab (anti-vascular endothelial growth factor [VEGF] agent) as compared to chemotherapy alone.<sup><xref ref-type="bibr" rid="bibr20-1076029611433644">20</xref></sup> The prevalence of arterial thromboembolus was 3.8% in the patients receiving Bevacizumab and chemotherapy combination, whereas it was found 1.7% in the other arm receiving chemotherapy alone.<sup><xref ref-type="bibr" rid="bibr21-1076029611433644">21</xref></sup></p>
<p>The present study was aimed to evaluate alterations in MPV and platicrit (PCT) in case of arterial and venous thromboses developed in the patients with cancer during the 18-month follow-up period.</p>
</sec>
<sec id="section2-1076029611433644" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>Study participants were obtained from Kayseri Education and Research Hospital Medical Oncology Department. New patients that have presented beginning from August 1, 2009, were included in the study and prospectively followed until March 11, 2011. Patients that developed arterial and venous thromboses within that period were recorded. Serum levels of <sc>d</sc>-dimer, arterial or venous Doppler according to the localization, ventilation–perfusion scintigraphy, cardiac evaluation, and cerebral tomography (and/or magnetic resonance imaging) were performed in case of suspicious thromboembolus. Thrombosis diagnosis was made based on the results of these analyses. Totally 43 patients were included in the study; of them, 56% had venous thrombosis and 44% had arterial thrombosis. The MPV and PCT values that were automatically calculated within the frame of routine complete blood count at the times of diagnosis and thrombosis were recorded on SPSS statistics program. Frequency analysis, crosstabs, and paired samples <italic>t</italic> test were used. A <italic>P</italic> value &lt;.05 was considered significant.</p>
</sec>
<sec id="section3-1076029611433644">
<title>Results</title>
<p>The data of all the 43 patients were evaluated. The mean age of the patients was 58 ± 10 years. Of the patients, 58% were male and 42% were female. Patients with breast and lung cancer accounted for the great proportion. Patient characteristics are given in <xref ref-type="table" rid="table1-1076029611433644">Table 1</xref>.</p>
<table-wrap id="table1-1076029611433644" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics.</p>
</caption>
<graphic alternate-form-of="table1-1076029611433644" xlink:href="10.1177_1076029611433644-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameter (n = 43)</th>
<th align="center">n/43</th>
<th align="center">Min</th>
<th align="center">Max</th>
<th align="center">Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td align="center">–</td>
<td>24</td>
<td>73</td>
<td>58 ± 10</td>
</tr>
<tr>
<td colspan="5">Gender</td>
</tr>
<tr>
<td> Male</td>
<td>25 (58%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Female</td>
<td>18 (42%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td colspan="5">Diagnosis</td>
</tr>
<tr>
<td> Breast cancer</td>
<td>12 (28%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Lung cancer</td>
<td>9 (21%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Colon cancer</td>
<td>7 (16%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Gastric cancer</td>
<td>6 (14%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Other</td>
<td>9 (21%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Arterial thrombosis</td>
<td>19 (44%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Pulmonary embolus</td>
<td>11 (58%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Myocardial infarction</td>
<td>4 (21%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Cerebrovascular accident</td>
<td>2 (11%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Aortic thrombosis</td>
<td>1 (5%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Lower extremity</td>
<td>1 (5%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Venous thrombosis</td>
<td>24 (56%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Lower extremity</td>
<td>19 (79%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td> Upper extremity</td>
<td>5 (21%)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The prevalence of venous thrombosis was 53% and the prevalence of arterial thrombosis was 47%. The most common site for thromboembolus was lower extremity (79%), whereas the most common site for arterial thromboembolus was pulmonary arteries (21%).</p>
<p>Considering the patient groups, thrombosis was more prevalent among the patients with breast cancer. The types of the disease and localization of thrombosis are shown in <xref ref-type="table" rid="table2-1076029611433644">Table 2</xref>. There were 7 arterial thromboembolus cases and 5 venous thromboembolus cases in breast cancer group. Breast cancer group was the only group with high prevalence of arterial thromboembolus. Thrombocyte, MPV, and PCT values of the patients at the time of diagnosis and thrombosis are given in <xref ref-type="table" rid="table3-1076029611433644">Table 3</xref>. There was a decrease in PLT and PCT values at the time of thrombosis, but it was not significant. The MPV values were statistically significantly low at the time of thrombosis as compared to those at the time of diagnosis (<italic>P</italic> = .041)</p>
<table-wrap id="table2-1076029611433644" position="float">
<label>Table 2.</label>
<caption>
<p>Diagnosis and Thromboembolus Localizations.</p>
</caption>
<graphic alternate-form-of="table2-1076029611433644" xlink:href="10.1177_1076029611433644-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="6">Thromboembolus Localizations</th>
<th>
</th>
</tr>
<tr>
<th>Diagnosis</th>
<th align="center">Upper Extremity</th>
<th align="center">Lower Extremity</th>
<th>PE</th>
<th>CVA</th>
<th>MI</th>
<th>Aorta</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>1</td>
<td>4</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
<td>19</td>
<td>12</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>43</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611433644">
<p>Abbreviations: PE, pulmonary embolism; CVA, cerebrovascular accident; MI, myocardial infraction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1076029611433644" position="float">
<label>Table 3.</label>
<caption>
<p>PLT Count, MPV, and PCT Values.</p>
</caption>
<graphic alternate-form-of="table3-1076029611433644" xlink:href="10.1177_1076029611433644-table3.tif"/>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Diagnosis (Mean)</th>
<th>Thrombosis (Mean)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLT count</td>
<td>277 ± 118</td>
<td>263 ± 113</td>
<td>.353</td>
</tr>
<tr>
<td>MPV</td>
<td>9.1 ± 1.4</td>
<td>8.6 ± 1.3</td>
<td>.041</td>
</tr>
<tr>
<td>PCT</td>
<td>0.25 ± 0.10</td>
<td>0.22 ± 0.09</td>
<td>.070</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1076029611433644">
<p>Abbreviations: PLT, platelet; MPV, mean platelet volume; PCT, platicrit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-1076029611433644">
<title>Discussion</title>
<p>Thrombosis and infection are the 2 leading causes of mortality in patients with cancer. The MPV elevation may indicate tendency toward thrombosis<sup><xref ref-type="bibr" rid="bibr2-1076029611433644">2</xref>,<xref ref-type="bibr" rid="bibr3-1076029611433644">3</xref></sup> and has been demonstrated in case of myocardial infarction and cerebrovascular embolus.<sup><xref ref-type="bibr" rid="bibr4-1076029611433644">4</xref>,<xref ref-type="bibr" rid="bibr5-1076029611433644">5</xref></sup> However, the present study failed to show MPV elevation in case of thrombosis developed in the patients with cancer. Contrarily, it was significantly low as compared to the MPV values at the time of cancer diagnosis.</p>
<p>Basic factors for tendency toward thrombosis in patients with cancer have been mentioned above. Secretion of procoagulant molecules from tumor cells (tissue factor being the most important), inactivation of fibrinolytic system, and thrombocyte activation are the 3 important factors in the pathogenesis of prothrombotic process.<sup><xref ref-type="bibr" rid="bibr16-1076029611433644">16</xref></sup> In a study, a pre-chemotherapy thrombocyte value higher than 350 000/mm<sup><xref ref-type="bibr" rid="bibr3-1076029611433644">3</xref></sup> has been suggested as the risk factor.<sup><xref ref-type="bibr" rid="bibr16-1076029611433644">16</xref></sup> In the present study, thrombocyte count was low at the time of thrombosis. Moreover, MPV value was also significantly low. Therefore, we can say that the role of thrombocytes as an initiating factor in cancer-related thrombosis is ignorable.</p>
<p>In conclusion, based on the result of the present study, we can say that thrombocytes are least responsible for the initiation of thrombosis in patients with cancer. However, cancer, to all points, is a strong thrombotic factor.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029611433644"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029611433644"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611433644">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Atherosclerosis: an inflammatory disease</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>340</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611433644">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greisenegger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Endler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tentschert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mannhalter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lalouschek</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?</article-title>. <source>Stroke</source>. <year>2004</year>;<volume>35</volume>(<issue>7</issue>):<fpage>1688</fpage>–<lpage>1691</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611433644">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Pathansali</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bath</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>Platelets and stroke</article-title>. <source>Vasc Med</source>. <year>1999</year>;<volume>4</volume>(<issue>3</issue>):<fpage>165</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611433644">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Klimesch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sunder-Plassmann</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease</article-title>. <source>Br J Haematol</source>. <year>2002</year>;<volume>117</volume>(<issue>2</issue>):<fpage>399</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611433644">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Malley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Langhorne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Elton</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Platelet size in stroke patients</article-title>. <source>Stroke</source>. <year>1995</year>;<volume>26</volume>(<issue>6</issue>):<fpage>995</fpage>–<lpage>999</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611433644">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Uysal</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Ozaydin</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Platelet indices in patients with pulmonary arterial hypertension</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2011</year>;</citation>
</ref>
<ref id="bibr7-1076029611433644">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tschoepe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Esser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schwippert</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Large platelets circulate in an activated state in diabetes mellitus</article-title>. <source>Semin Thromb Hemost</source>. <year>1991</year>;<volume>17</volume>(<issue>4</issue>):<fpage>433</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611433644">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turhan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Coban</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Inan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yalcin</surname>
<given-names>AN</given-names>
</name>
</person-group>. <article-title>Increased mean platelet volume in chronic hepatitis B patients with inactive disease</article-title>. <source>Med Sci Monit</source>. <year>2010</year>;<volume>16</volume>(<issue>4</issue>):<fpage>CR202</fpage>–<lpage>CR205</lpage>.</citation>
</ref>
<ref id="bibr9-1076029611433644">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bath</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Butterworth</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Platelet size: measurement, physiology and vascular disease</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>1996</year>;<volume>7</volume>(<issue>2</issue>):<fpage>157</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611433644">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Solymoss</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism</article-title>. <source>J Clin Oncol</source>. <year>2003</year>;<volume>21</volume>(<issue>22</issue>):<fpage>4194</fpage>–<lpage>4199</lpage>.</citation>
</ref>
<ref id="bibr11-1076029611433644">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maraveyas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?</article-title>. <source>Br J Cancer</source>. <year>2009</year>;<volume>100</volume>(<issue>12</issue>):<fpage>1837</fpage>–<lpage>1841</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611433644">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levitan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dowlati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Remick</surname>
<given-names>SC</given-names>
</name>
<etal/>
</person-group>. <article-title>Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data</article-title>. <source>Medicine (Baltimore)</source>.. <year>1999</year>;<volume>78</volume>(<issue>5</issue>):<fpage>285</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611433644">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Streiff</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>Anticoagulation in the management of venous thromboembolism in the cancer patient</article-title>. <source>J Thromb Thrombolysis</source>. <year>2011</year>;<volume>31</volume><issue>(3)</issue>:<fpage>282</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611433644">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heit</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Silverstein</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Mohr</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Petterson</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>O’Fallon</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Melton</surname>
<given-names>LJ</given-names>
</name>
</person-group>. <article-title>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study</article-title>. <source>Arch Intern Med</source>. <year>2000</year>;<volume>160</volume>(<issue>6</issue>):<fpage>809</fpage>–<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611433644">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adess</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eisner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Godwin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Messmore</surname>
<given-names>HL</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Wehrmacher</surname>
<given-names>WH</given-names>
</name>
</person-group>. <article-title>Thromboembolism in cancer patients: pathogenesis and treatment</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2006</year>;<volume>12</volume>(<issue>3</issue>):<fpage>254</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611433644">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>AYY</given-names>
</name>
<name>
<surname>Khorana</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Vascular Events</article-title>. In: <person-group person-group-type="editor"><name><surname>DeVita</surname><given-names>VT</given-names></name><name><surname>Lawrence</surname><given-names>TS</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group>, eds. <source>Cancer Principles &amp; Practice Oncology</source>. <edition>8th ed</edition>. <year>2008</year>; <fpage>2634</fpage>.</citation>
</ref>
<ref id="bibr17-1076029611433644">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chew</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Wun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>White</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Incidence of venous thromboembolism and its effect on survival among patients with common cancers</article-title>. <source>Arch Intern Med</source>. <year>2006</year>;<volume>166</volume>(<issue>4</issue>):<fpage>458</fpage>.</citation>
</ref>
<ref id="bibr18-1076029611433644">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blom</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Doggen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Osanto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosendaal</surname>
<given-names>FR</given-names>
</name>
</person-group>. <article-title>Malignancies, prothrombotic mutations, and the risk of venous thrombosis</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>6</issue>):<fpage>715</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611433644">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khorana</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Culakova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Refaai</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lyman</surname>
<given-names>GH</given-names>
</name>
</person-group>. <article-title>Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer</article-title>. <source>Arch Intern Med</source>.. <year>2008</year>;<volume>168</volume>(<issue>21</issue>):<fpage>2377</fpage>–<lpage>2381</lpage>.</citation>
</ref>
<ref id="bibr20-1076029611433644">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranpura</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hapani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials</article-title>. <source>Acta Oncol</source>. <year>2010</year>;<volume>49</volume>(<issue>3</issue>):<fpage>287</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr21-1076029611433644">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scappaticci</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Skillings</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Holden</surname>
<given-names>SN</given-names>
</name>
<etal/>
</person-group>. <article-title>Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab</article-title>. <source>J Natl Cancer Inst</source>. <year>2007</year>;<volume>99</volume>(<issue>16</issue>):<fpage>1232</fpage>–<lpage>1239</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>